BioMed Research International / 2011 / Article / Tab 2

Review Article

Myelodysplastic Syndrome and Histone Deacetylase Inhibitors: “To Be or Not to Be Acetylated”?

Table 2

Selected HDAC inhibitors: structural class, compound, isotype selectivity, and study phase—an overview (according to Batty et al. [14] and Schneider-Stock and Ocker [81]).

StructuralHDAC inhibitor (synonyms, abbreviation, supplier)Class selectivityStudy phase

Hydroxamic acidsm-carboxycinnamic acid bis-hydroxamide (CBHA)
Oxamflatin
Belinostat (PXD-101, Curagen Corp/TopoTarget A/S)I, IIa, IIb, IVII
PyroxamideI
Scriptaid
Superoylamilide hydroxamic acid (SAHA, Vorinostat)I, IIa, IIb, IVFDA approval (CTCL)
Trichostatin A (TSA)I, II
Panobinostat (LBH-589; Novartis AG)I, IIa, IIb, IVII

Cyclic tretapeptidesApicidinI, II
Romidepsin (FK-228, FR-901228; Gloucester Pharmaceuticals Inc)I, IIII
Trapoxin-histone acetylase (TPX-HA) analog (CHAP)
Trapoxin

BenzamidesTacedinaline (CI-994; Pfizer Inc)
Entinostat SNDX-275 (MS-275; Syndax Pharmaceuticals Inc)I, IIII

Short-chain fatty acidsButyrateI, IIaI
Valproic acidI, IIaI